Ensysce Biosciences, Inc. (NASDAQ:ENSC – Get Free Report) saw a large decline in short interest during the month of November. As of November 30th, there was short interest totalling 115,300 shares, a decline of 97.6% from the November 15th total of 4,850,000 shares. Based on an average trading volume of 1,760,000 shares, the short-interest ratio is presently 0.1 days.
Ensysce Biosciences Price Performance
ENSC stock traded down $0.50 during mid-day trading on Friday, hitting $5.62. 133,770 shares of the stock were exchanged, compared to its average volume of 534,941. Ensysce Biosciences has a 12 month low of $2.12 and a 12 month high of $30.90. The business has a fifty day moving average price of $6.93 and a 200 day moving average price of $6.66. The stock has a market capitalization of $7.36 million, a price-to-earnings ratio of -0.20 and a beta of 0.60.
Ensysce Biosciences (NASDAQ:ENSC – Get Free Report) last released its quarterly earnings data on Tuesday, November 12th. The company reported $1.05 earnings per share for the quarter, beating analysts’ consensus estimates of ($4.50) by $5.55. Ensysce Biosciences had a negative return on equity of 292.81% and a negative net margin of 179.26%. The firm had revenue of $3.42 million during the quarter, compared to analyst estimates of $0.25 million. As a group, equities analysts forecast that Ensysce Biosciences will post -12.44 EPS for the current fiscal year.
Hedge Funds Weigh In On Ensysce Biosciences
About Ensysce Biosciences
Ensysce Biosciences, Inc, a clinical-stage pharmaceutical company, engages in developing various prescription drugs for severe pain relief in opioid misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection (TAAP) platform, an abuse-resistant opioid prodrug technology; and Multi-Pill Abuse Resistance (MPAR) platform, an over-dose protection opioid prodrug technology.
Featured Articles
- Five stocks we like better than Ensysce Biosciences
- What Is WallStreetBets and What Stocks Are They Targeting?
- FinWise Bancorp’s CEO Talks Strategy Behind Fintech Success
- The How And Why of Investing in Oil Stocks
- Broadcom: Turning the Mag 7 Into 8 Trillion-Dollar Tech Giants
- Uptrend Stocks Explained: Learn How to Trade Using Uptrends
- SoundHound AI: Can Its Meteoric Rise Sustain Into 2025?
Receive News & Ratings for Ensysce Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ensysce Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.